Q-omics provides the consensus-scored CRACR2B profile across patient tissues and cancer cell-line models. CRACR2B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CRACR2B is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CRACR2B RNA expression shows 15,807 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, COAD, and ESCA as cancer lineages where CRACR2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRACR2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRACR2B survival associations across molecular data types. CRACR2B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRACR2B RNA expression–survival associations across cancer types. High CRACR2B expression shows unfavorable associations in LUSC, but favorable associations in HNSC, SKCM, KIRP, BLCA and STAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CRACR2B RNA expression.
This table summarizes CRACR2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CRACR2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRACR2B shows lower tumor expression in LUSC and higher tumor expression in COAD, THCA, LIHC, KIRC and UCEC. The COAD box plot shows higher CRACR2B RNA expression in tumor versus normal tissue (log2 FC = +0.967, t-test p < 0.001).
This table shows molecular features associated with CRACR2B in patient tissues and cancer cell lines. In patient samples, CRACR2B shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CRACR2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
